PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer

Thumbnail Image
Cox_et_al__9March.pdf(5.08 MB)
Accepted Version
Supplementary Figure 1 07Jan.pdf(944.88 KB)
Supplementary Figure 1
Supplementary Figure 2 07Jan.pdf(697.7 KB)
Supplementary Figure 2
Supplementary Figure 4 08Mar2019.pdf(602.79 KB)
Supplementary Figure 4
Cox, Orla T.
Edmunds, Shelley J.
Simon-Keller, Katja
Li, Bo
Moran, Bruce
Buckley, Niamh E.
Bustamante- Garrido, Milán F.
Healy, Nollaig
O'Flanagan, Ciara H.
Gallagher, William M.
Journal Title
Journal ISSN
Volume Title
American Association for Cancer Research
Research Projects
Organizational Units
Journal Issue
The PDLIM2 protein regulates stability of transcription factors including NF-κB and STATs in epithelial and hemopoietic cells. PDLIM2 is strongly expressed in certain cancer cell lines that exhibit an Epithelial-to-Mesenchymal phenotype, and its suppression is sufficient to reverse this phenotype. PDLIM2 supports the epithelial polarity of non-transformed breast cells, suggesting distinct roles in tumor suppression and oncogenesis. To better understand its overall function, we investigated PDLIM2 expression and activity in breast cancer. PDLIM2 protein was present in 60% of tumors diagnosed as triple-negative breast cancer (TNBC), and only 20% of other breast cancer subtypes. High PDLIM2 expression in TNBC was positively correlated with adhesion signaling and β-catenin activity. Interestingly, PDLIM2 was restricted to the cytoplasm/membrane of TNBC cells and excluded from the nucleus. In breast cell lines, PDLIM2 retention in the cytoplasm was controlled by cell adhesion, and translocation to the nucleus was stimulated by IGF-1 or TGFβ. Cytoplasmic PDLIM2 was associated with active β-catenin and ectopic expression of PDLIM2 was sufficient to increase β-catenin levels and its transcriptional activity in reporter assays. Suppression of PDLIM2 inhibited tumor growth in vivo, whereas over-expression of PDLIM2 disrupted growth in 3D cultures. These results suggest that PDLIM2 may serve as a predictive biomarker for a large subset of TNBC whose phenotype depends on adhesion-regulated β-catenin activity and which may be amenable to therapies that target these pathways.
Predictive biomarker , PDLIM2 , Triple-negative breast cancer , TNBC , Adhesion-regulated β-catenin activity
Cox, O. T., Edmunds, S. J., Simon-Keller, K., Li, B., Moran, B., Buckley, N. E., Bustamante-Garrido, M., Healy, N., O'Flanagan, C. H., Gallagher, W. M., Kennedy, R. D., Bernards, R., Caldas, C., Chin, S.-F., Marx, A. and O'Connor, R. (2019) ‘PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer', Cancer Research, 79(10), pp. 2619-2633. doi: 10.1158/0008-5472.CAN-18-2787
© 2019, American Association for Cancer Research. All rights reserved.